Gain Therapeutics (GANX) said Monday it has received approval in Australia to start a phase 1b trial of GT-02287, the company's lead allosteric small molecule in clinical development to treat Parkinson's disease with or without a GBA1 mutation.
The main objective of the phase 1b trial is to evaluate the safety and tolerability of GT-02287 and follows the completed phase 1 study in healthy volunteers that showed it was safe, well-tolerated and increased glucocerebrosidase activity, the company said.
The company said it expects to complete enrollment for the phase 1b study to be completed in the spring of 2025 and data to be released in the middle of that year.
Shares of Gain Therapeutics were up 17% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。